Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding disorders that involve deficiency of factor VIII and von Willebrand factor. It is used in clinical practice for:

• Prophylaxis of bleeding episodes in hemophilia A
• On‑demand treatment of acute bleeds in hemophilia A
• Surgical support in patients with hemophilia A
• Treatment of von Willebrand disease types 1, 2 and 3
• Management of combined factor VIII/VWF deficiency during bleeding crises

Side effects of Haemate P reflect the typical profile of plasma‑derived factor concentrates. They are reported in clinical use and post‑marketing surveillance.

Common

• Headache
• Fever or chills
• Nausea or vomiting
• Injection site erythema or swelling
• Mild arthralgia

Serious

• Allergic reactions including anaphylaxis
• Development of inhibitors (neutralizing antibodies) to factor VIII or VWF
• Thromboembolic events
• Renal dysfunction in rare cases
• Severe hypertension

When prescribing or administering Haemate P, clinicians should consider several safety aspects. Important precautions include:

• Assessing patient history for inhibitors to factor VIII or VWF before use
• Monitoring for signs of allergic reaction during and after infusion
• Evaluating renal and hepatic function in patients with pre‑existing disease
• Using caution in patients with a history of thrombosis or cardiovascular disease
• Ensuring proper aseptic technique to prevent contamination
• Adjusting dosage based on individual pharmacokinetic response when available

Haemate P may interact with other agents that affect hemostasis or immune response. Interaction considerations are:

Avoid

• Concurrent use of pro‑coagulant agents (e.g., activated prothrombin complex concentrates) without specialist guidance
• High‑dose aspirin or other non‑steroidal anti‑inflammatory drugs that increase bleeding risk

Use with caution

• Antifibrinolytic drugs such as tranexamic acid (monitor for thrombotic signs)
• Immunosuppressive therapies that may alter inhibitor development
• Other plasma‑derived products (potential additive viral risk)
• Vaccines administered shortly before or after infusion (monitor immune response)